Cargando…

Tumor markers used in monitoring the tumor recurrence in patients with colorectal cancer

BACKGROUND AND AIMS: The aim of this study was to investigate the value of serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) correlated with some tissue molecules as predictive markers for recurrence in colon cancer. METHODS: A total of 30 patients diagnosed with colon cancer s...

Descripción completa

Detalles Bibliográficos
Autores principales: BURZ, CLAUDIA, AZIZ, BEN YOUSSEF MOHAMED, BĂLĂCESCU, LOREDANA, LELUŢIU, LUMINIŢA, BUIGA, RAREŞ, SAMASCA, GABRIEL, IRIMIE, ALEXANDRU, LISENCU, COSMIN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iuliu Hatieganu University of Medicine and Pharmacy 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990433/
https://www.ncbi.nlm.nih.gov/pubmed/27547057
http://dx.doi.org/10.15386/cjmed-635
_version_ 1782448700368355328
author BURZ, CLAUDIA
AZIZ, BEN YOUSSEF MOHAMED
BĂLĂCESCU, LOREDANA
LELUŢIU, LUMINIŢA
BUIGA, RAREŞ
SAMASCA, GABRIEL
IRIMIE, ALEXANDRU
LISENCU, COSMIN
author_facet BURZ, CLAUDIA
AZIZ, BEN YOUSSEF MOHAMED
BĂLĂCESCU, LOREDANA
LELUŢIU, LUMINIŢA
BUIGA, RAREŞ
SAMASCA, GABRIEL
IRIMIE, ALEXANDRU
LISENCU, COSMIN
author_sort BURZ, CLAUDIA
collection PubMed
description BACKGROUND AND AIMS: The aim of this study was to investigate the value of serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) correlated with some tissue molecules as predictive markers for recurrence in colon cancer. METHODS: A total of 30 patients diagnosed with colon cancer stage II or III who underwent optimal surgery were enrolled in study. Tumor markers CEA and CA 19-9 were determined before surgery. Tumor samples were prepared using tissue microarray kit (TMA) then stained for different cellular markers (Ki 67, HER2, BCL2, CD56, CD4, CD8) and analyzed using Inforatio programme for quantitative determination. All patients received standard adjuvant treatment, which consisted of eight cycles chemotherapy type XELOX. The patients were followed up for 3 years. RESULTS: Upon 3 years follow-up, 67% of patients developed tumor relapse, the most common site of metastasis being the liver. No correlations were observed between either serum or tissue tumor markers and the risk of tumor relapse. CONCLUSION: Over 50% of patients with colon cancer who had optimal treatment developed metastasis. No statistically significant predictive value for investigated molecules was found. Future studies are needed to confirm the use of molecular markers in monitoring patients with colorectal cancer
format Online
Article
Text
id pubmed-4990433
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Iuliu Hatieganu University of Medicine and Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-49904332016-08-19 Tumor markers used in monitoring the tumor recurrence in patients with colorectal cancer BURZ, CLAUDIA AZIZ, BEN YOUSSEF MOHAMED BĂLĂCESCU, LOREDANA LELUŢIU, LUMINIŢA BUIGA, RAREŞ SAMASCA, GABRIEL IRIMIE, ALEXANDRU LISENCU, COSMIN Clujul Med Original Research BACKGROUND AND AIMS: The aim of this study was to investigate the value of serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) correlated with some tissue molecules as predictive markers for recurrence in colon cancer. METHODS: A total of 30 patients diagnosed with colon cancer stage II or III who underwent optimal surgery were enrolled in study. Tumor markers CEA and CA 19-9 were determined before surgery. Tumor samples were prepared using tissue microarray kit (TMA) then stained for different cellular markers (Ki 67, HER2, BCL2, CD56, CD4, CD8) and analyzed using Inforatio programme for quantitative determination. All patients received standard adjuvant treatment, which consisted of eight cycles chemotherapy type XELOX. The patients were followed up for 3 years. RESULTS: Upon 3 years follow-up, 67% of patients developed tumor relapse, the most common site of metastasis being the liver. No correlations were observed between either serum or tissue tumor markers and the risk of tumor relapse. CONCLUSION: Over 50% of patients with colon cancer who had optimal treatment developed metastasis. No statistically significant predictive value for investigated molecules was found. Future studies are needed to confirm the use of molecular markers in monitoring patients with colorectal cancer Iuliu Hatieganu University of Medicine and Pharmacy 2016 2016-07-28 /pmc/articles/PMC4990433/ /pubmed/27547057 http://dx.doi.org/10.15386/cjmed-635 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
spellingShingle Original Research
BURZ, CLAUDIA
AZIZ, BEN YOUSSEF MOHAMED
BĂLĂCESCU, LOREDANA
LELUŢIU, LUMINIŢA
BUIGA, RAREŞ
SAMASCA, GABRIEL
IRIMIE, ALEXANDRU
LISENCU, COSMIN
Tumor markers used in monitoring the tumor recurrence in patients with colorectal cancer
title Tumor markers used in monitoring the tumor recurrence in patients with colorectal cancer
title_full Tumor markers used in monitoring the tumor recurrence in patients with colorectal cancer
title_fullStr Tumor markers used in monitoring the tumor recurrence in patients with colorectal cancer
title_full_unstemmed Tumor markers used in monitoring the tumor recurrence in patients with colorectal cancer
title_short Tumor markers used in monitoring the tumor recurrence in patients with colorectal cancer
title_sort tumor markers used in monitoring the tumor recurrence in patients with colorectal cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990433/
https://www.ncbi.nlm.nih.gov/pubmed/27547057
http://dx.doi.org/10.15386/cjmed-635
work_keys_str_mv AT burzclaudia tumormarkersusedinmonitoringthetumorrecurrenceinpatientswithcolorectalcancer
AT azizbenyoussefmohamed tumormarkersusedinmonitoringthetumorrecurrenceinpatientswithcolorectalcancer
AT balacesculoredana tumormarkersusedinmonitoringthetumorrecurrenceinpatientswithcolorectalcancer
AT lelutiuluminita tumormarkersusedinmonitoringthetumorrecurrenceinpatientswithcolorectalcancer
AT buigarares tumormarkersusedinmonitoringthetumorrecurrenceinpatientswithcolorectalcancer
AT samascagabriel tumormarkersusedinmonitoringthetumorrecurrenceinpatientswithcolorectalcancer
AT irimiealexandru tumormarkersusedinmonitoringthetumorrecurrenceinpatientswithcolorectalcancer
AT lisencucosmin tumormarkersusedinmonitoringthetumorrecurrenceinpatientswithcolorectalcancer